Type of leukemia-Acute Myeloid Leukemia (AML) - Page 2 of 8 Posts on Medivizor
Navigation Menu

Type of leukemia-Acute Myeloid Leukemia (AML) Posts on Medivizor

Combining all-trans-retinoic acid, arsenic trioxide and idarubicin for the treatment of acute promyelocytic leukemia 

Combining all-trans-retinoic acid, arsenic trioxide and idarubicin for the treatment of acute promyelocytic leukemia 

Posted by on Jul 11, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of the combination of all-trans-retinoic acid (Vesanoid), arsenic trioxide (Trisenox), and idarubicin (Idamycin) as front-line treatment for acute promyelocytic leukemia.  This study concluded that this combination is safe and effective for these...

Read More

Impact of graft cryopreservation on allogeneic hematopoietic stem cell transplant outcomes using post-transplant cyclophosphamide

Impact of graft cryopreservation on allogeneic hematopoietic stem cell transplant outcomes using post-transplant cyclophosphamide

Posted by on Jun 21, 2020 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to compare outcomes of allogeneic hematopoietic stem cell transplant (alloHSCT) using cryopreserved (frozen) and fresh grafts in patients with blood cancers who received post-transplant cyclophosphamide (Cytoxan).   This study concluded that cryopreservation (CP) does...

Read More

Differentiation syndrome in patients of IDH-mutated acute myeloid leukemia treated with ivosidenib and enasidenib

Differentiation syndrome in patients of IDH-mutated acute myeloid leukemia treated with ivosidenib and enasidenib

Posted by on Jun 7, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the occurrence of differentiation syndrome (DS) in patients with IDH-mutated acute myeloid leukemia (AML) under ivosidenib (Tibsovo) and enasidenib (Idhifa) therapy. The authors found that DS is a common and adverse condition in such patients. Some background Mutations or changes in the isocitrate dehydrogenase (IDH)...

Read More

The effects of smoking on predicted treatment outcomes in patients with acute myeloid leukemia

The effects of smoking on predicted treatment outcomes in patients with acute myeloid leukemia

Posted by on May 16, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated how smoking habits affect the predicted treatment outcomes in patients with acute myeloid leukemia (AML) under intense chemotherapy. The authors found that smoking status was related to poor overall survival in such patients. Some background Patient-related factors such as lifestyle choice and additional medical...

Read More

Treating patients with high risk acute promyelocytic leukemia (APL) with ATRA, arsenic trioxide and gemtuzumab ozogamicin

Posted by on May 10, 2020 in Leukemia | 0 comments

In a nutshell The study evaluated the effectiveness and safety of combing all-trans retinoic acid (ATRA; Vesanoid), arsenic trioxide (ATO; Trisenox), and gemtuzumab ozogamicin (GO; Milotarg) in treating patients with high risk (HR) acute promyelocytic leukemia (APL). The authors found that the combination therapy was effective and well...

Read More

Comparing outcomes in acute myeloid leukemia patients treated with FLAG with/without idarubicin vs traditional 3+7 treatment

Posted by on Apr 18, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to compare post-remission survival for patients with acute myeloid leukemia treated with 2 different regimens. This study concluded that FLAG with or without idarubicin treatment has better post-remission survival when compared to standard 3+7 treatment for these patients.   Some background...

Read More